APEXIGEN, INC. This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Apexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company's licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.25% | 103B | |
| +1.62% | 95.28B | |
| +2.56% | 22.15B | |
| -15.74% | 21.02B | |
| -8.21% | 18.15B | |
| -41.01% | 16.73B | |
| -13.92% | 16.05B | |
| +3.91% | 13.68B | |
| +34.76% | 12.17B |
